… -1-based therapies, and emphasizes current developments in incretin research that are
relevant to cardiovascular risk and disease, as well as treatment with GLP-1 receptor agonists. …

… The discontinuation of the aggressive versus less aggressive arm of the Action to Control
Cardiovascular Risk in Diabetes (ACCORD) 1 trial due to increased mortality in subjects who …

… of those treatments in the prevention of cardiovascular risk in type 2 diabetic patients. … shown
that GLP-1 has several potentially beneficial actions on cardiovascular risk. Some of those, …

… Overall, GLP-1 RA seem to have a beneficial effect on traditional cardiovascular risk factors
… assessment of the effects of GLP-1 RA on MACE, mortality and cardiovascular risk factors. …

… We present here the effect of liraglutide on biomarkers for cardiovascular risk in patients …
and non-cardiovascular biomarker results of this study have been described previously [1]. The …

… the role of GLP-1 as a potential novel biomarker of cardiovascular risk will foster our …
have been well described there is no robust data on gut hormones and cardiovascular risk. …

… and blood glucose.1 These monitored CV risk factors form the focus of the present review. …
present review was the CV risk factors routinely monitored in RCTs, other CV risk factors exist, …

… Here we review how GLP-1 and clinically approved GLP-1R agonists … risk of developing
cardiovascular disease. We discuss how GLP-1R agonists modify inflammation, cardiovascular …

… ) receptor agonists have been shown to be effective in reducing major adverse cardiac … all
known to be associated with cardiovascular risk. GLP-1 receptor agonists have been shown to …

… concentrations of MCP-1. It is thus critically important to further understand the role of GIP
in the context of dual GIP and GLP-1 receptor agonism on key cardiovascular risk factors. …